Iridex Reports 7 Percent Q2 Revenue Gain

Iridex (IRIX) reported Q2 2025 results, achieving a 7.0% year-over-year revenue increase to $13.6 million and narrowing its GAAP net loss to $0.06 per share, primarily driven by a significant 28% reduction in operating expenses. While the company reached positive non-GAAP adjusted EBITDA of $0.02 million, gross margins compressed to 34.5% due to higher manufacturing costs and product mix. A key concern remains the decline in recurring Cyclo G6 probe unit sales, despite higher system placements, signaling potential pressure on future predictable revenue streams. Management reiterated a focus on achieving annual cash flow breakeven and positive adjusted EBITDA through continued expense discipline.

Analysis

Iridex (IRIX) reported mixed Q2 2025 results, demonstrating significant progress in operational discipline but revealing underlying weakness in its core business model. Top-line revenue grew a modest 7.0% year-over-year to $13.6 million, while a substantial 28% reduction in operating expenses was the primary driver behind the narrowed GAAP net loss of $0.06 per share, a marked improvement from a $0.16 loss in the prior-year quarter. This cost control culminated in positive non-GAAP adjusted EBITDA of $0.02 million, achieving management's goal of breakeven on this metric. However, this bottom-line improvement is overshadowed by a severe contraction in GAAP gross margin, which fell 620 basis points to 34.5% due to higher manufacturing costs and an unfavorable sales mix. The most critical concern is the erosion of the recurring revenue stream; despite a 25% increase in Cyclo G6 system placements, sales of the associated high-margin consumable probes declined to 13,100 units from 15,100 year-over-year. This disconnect challenges the long-term thesis of predictable revenue from an expanding installed base and suggests that management's current focus is on stability rather than growth, as evidenced by the lack of formal revenue guidance.

Key Decisions for Investors

• Investors should weigh the company's successful cost management, which drove a narrower net loss and positive adjusted EBITDA, against the significant deterioration in gross margins and the concerning decline in recurring probe sales.
• Monitor future reports closely for a reversal in the declining trend of Cyclo G6 probe sales, as a recovery is critical to validating the long-term value of the growing installed system base and the recurring revenue thesis.
• Given the absence of revenue growth guidance and the defensive focus on achieving breakeven, a potential strategy is to hold existing positions while awaiting tangible evidence of margin stabilization and a return to consumables growth before considering new capital allocation.